Ahead of the FDA’s advisory meeting to review Pfizer’s COVID-19 booster application, agency staffers voiced skepticism about the need to quickly roll out follow-up shots. As it stands, authorized vaccines are doing their job, the staffers said.
In briefing documents ahead of Friday’s meeting, FDA reviewers said that while “some observational studies” suggest the efficacy of Pfizer two-dose vaccine wanes over time, overall data “indicate that currently US-licensed or authorized COVID-19 vaccines still afford protection against severe COVID-19 disease and death in the United States.”
